Rebekah Edwards
Family · Phoenix, AZNPI 1225444052
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 93.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $26,691 and has fallen 65.2% since, to $9,289 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $291.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$47K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- United Therapeutics Corporation$514
- Actelion Pharmaceuticals US, Inc.$251
- Abbott$229
- Regeneron Healthcare Solutions, Inc.$173
- plus $888 from 19 others
What the payments were for
- Consulting fees$16,00531%
- Speaking & faculty fees$21,13541%
- Travel & lodging$9,74519%
- Food & beverage$3,7197%
- Education$4031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 104 | $47,455 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $1,496 |
| United Therapeutics Corporation | 10 | $514 |
| Actelion Pharmaceuticals US, Inc. | 8 | $251 |
| Abbott | 3 | $229 |
| Regeneron Healthcare Solutions, Inc. | 3 | $173 |
| Insmed, Inc. | 6 | $112 |
| Chiesi USA, Inc. | 2 | $96 |
| Mylan Specialty L.p. | 3 | $91 |
| Baxter Healthcare | 5 | $79 |
| Amgen | 4 | $68 |
| Philips North America LLC | 3 | $58 |
| Grifols USA, LLC | 2 | $53 |
| AstraZeneca | 3 | $52 |
| Electromed, Inc. | 3 | $38 |
| Pharmacosmos Therapeutics Inc. | 1 | $33 |
| Vifor Pharma, Inc. | 1 | $32 |
| AbbVie | 1 | $29 |
| Sanofi | 2 | $29 |
| Merck | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $21 |
| Shionogi Inc | 1 | $20 |
| GSK | 1 | $15 |
| Genentech, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,006 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 35 | $942,557 |
| OfevNintedanib Esylate | 68 | $904,265 |
| Tyvaso DpiTreprostinil | 18 | $538,831 |
| ZemairaAlpha-1-Proteinase Inhibitor | 36 | $355,550 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $269,805 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $158,101 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $120,872 |
| Pirfenidone | 25 | $77,323 |
| Spiriva RespimatTiotropium Bromide | 12 | $13,155 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,158 |
| EliquisApixaban | 15 | $8,352 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,704 |
| Mycophenolate Mofetil | 66 | $5,419 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,703 |
| Itraconazole | 20 | $2,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $47,455 | $917,42080 claims |
| Grifols USA, LLCProlastin C | $53 | $269,80522 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,496 | $158,10113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $15 | $132,030135 claims |
| AstraZenecaSymbicort | $52 | $7,70418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
- Susan HawrylkiwPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.